Proteovista

Executive Summary

Proteovista is a San Diego-based proteomics and diagnostics company developing SNAP (Specificity and Affinity for Protein) microarrays to determine and visualize the complete DNA sequence specificity of any DNA-binding molecule. Founded in 2015, the company's proprietary platform enables high-throughput characterization of protein-DNA interactions across millions of sequences, offering a comprehensive sequence specificity landscape (SSL) visualization tool. This technology has broad applications in drug discovery, synthetic biology, and diagnostic development, particularly for understanding transcription factor networks and off-target effects of gene-editing tools. While the company has not disclosed funding rounds, valuation, or revenue, its novel approach addresses a critical bottleneck in molecular biology. However, as a private, likely early-stage entity with limited public information, Proteovista faces significant commercialization and scaling challenges. The conviction score of 60 reflects the innovative technology offset by uncertain market traction and lack of disclosed milestones.

Upcoming Catalysts (preview)

• Q2 2027Strategic partnership or licensing deal with biopharma company40% success
• Q4 2026Series A funding round announcement50% success
• Q3 2026Publication of validation data in peer-reviewed journal70% success